DyeVert™ System for Contrast Monitoring in At-Risk Patients Undergoing Angiography: A Real-World Registry

UnknownOBSERVATIONAL
Enrollment

10,000

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Patients at Risk for Developing Contrast-induced Nephropathy
Interventions
DEVICE

DyeVert™ Contrast Reduction Systems

Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.

Trial Locations (11)

25702

St. Mary's Medical Center, Huntington

26506

West Virginia University, Morgantown

30033

Atlanta VA Medical Center, Decatur

30322

Emory Healthcare, Atlanta

33016

Steward Palmetto General Hospital, Hialeah

38801

North Mississippi Medical Center, Tupelo

41017

St. Elizabeth Healthcare, Edgewood

66211

Midwest Heart & Vascular Specialists, Overland Park

78229

The University of Texas Health Science Center, San Antonio

78251

CHRISTUS Health-Westover Hills, San Antonio

06102

Hartford Healthcare, Hartford

Sponsors
All Listed Sponsors
lead

Osprey Medical, Inc

INDUSTRY